Карведилол – эффективное средство терапии сердечной недостаточности


М.В. Журавлева

В многочисленных контролируемых исследованиях последних лет продемонстрирована способность бета-адреноблокаторов уменьшать выраженность симптоматики хронической сердечной недостаточности (ХСН). Более того, показано, что некоторые бета-адреноблокаторы, в т. ч. карведилол, существенно снижают смертность больных ХСН. Рассматриваются фармакодинамика и фармакокинетика карведилола, определяющие его клиническую эффективность при ХСН. Приводятся результаты клинических исследований по применению карведилола у пациентов с ХСН ишемической и неишемической природы. Они свидетельствуют о том, что карведилол улучшает функцию левого желудочка, снижает заболеваемость и смертность у пациентов с ХСН разной степени тяжести и должен рассматриваться у данной категории больных в качестве стандартного лечения. Данные доказательной медицины стали основанием для включения бета-адреноблокаторов, в частности карведилола, в современные рекомендации по лечению ХСН. Отмечается, что по влиянию на смертность при ХСН карведилол превосходит метопролол.

Литература






  1. Feuerstein G, Yue T-L, Ma X, et al. Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis 1998;41(suppl. 1):17–24.
  2. Ruffolo Jr RR, Feuerstein GZ. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. J Cardiovasc Pharmacol 1998;32(suppl. 1):22–30.
  3. Bristow M, Gibert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2800–06.
  4. Keating GM, Jarvis B. Carvedilol. Review of its use in chronic heart failure. Drugs 2003;63:1698–40.
  5. Bristow M. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997;80(11 A):26L–40L.
  6. Dunn CJ, Lea AP, Wagstaff AJ. Carvedilol: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1997;54:161–85.
  7. Gibbons RJ, Chatteerjee K, Daley J, et al. ACC/AHA/ACP–ASIM guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 1999;33:2092–97.
  8. Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet 1994;26:335–46.
  9. Von Mollendorff E, Reiff K, Neugebauer G. Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur J Clin Pharmacol 1987;33:511–13.
  10. Carlson W, Oberg K. Clinical pharmacology of carvedilol. J Cardiovasc Pharmacol Ther 1999;4:205–18.
  11. GlaxoSmithKline. COREG® (carvedilol) tablets: prescribing information. http://www.gsk.com.
  12. Oldham HG, Clarke SE. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+) and S(–)carvedilol. Drug Metab Dispos 1997;25:970–77.
  13. Neugebauer G, Akpan W, von Mollendorff E, et al. Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol 1987;10(suppl. 11):85–88.
  14. Morgan T, Anderson A, Cripps J, et al. Pharmacokinetics of carvedilol in older and younger patients. J Hum Hypert 1990;4:709–15.
  15. Gehr TWB, Tenero DM, Boyle DA, et al. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol 1999;55:269–77.
  16. Neugebauer G, Gabor M, Reiff K. Pharmacokinetics and bioavilability of carvedilol in patients with liver cirrhosis. Drugs 1988;36(suppl. 6):148–54.
  17. Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe chronic heart failure. US Carvedilol Heart Failure Study Group. J Card Fail 1997;3:173–39.
  18. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800–06.
  19. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation 1996;94:2793–99.
  20. Doughty RN, Whalley GA, Gamble G, et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1997;29:1060–66.
  21. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349–55.
  22. McMurray JJV. Major b blocker mortality trials in chronic heart failure: a critical review. Heart 1999;82(suppl 4):IV14–IV22.
  23. Australia. New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375–80.
  24. Joglar JA, Acusta AP, Shusterman NH, et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 2001:142:498–501.
  25. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure. J Am Coll Cardiol 1995;25:1225–31.
  26. Cice G, Ferrara L, Di Bennedetto A, et al. Dilated cardiomyopathy in dialysis patients – beneficial effects of carvedilol; a double-blind, placebo-controlled trial. J Am Coll Cardiol 2001;37:407–11.
  27. Cice G, Ferrara L, D’Andrea, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003;41:1438–44.
  28. Macfarlane PW, Murray GD, McGowan J, et al. Analysis of 24 hour ambulatory ECGs from the CHRISTMAS study (abstract no. 3026). Circulation 2002;106(suppl. 19):613.
  29. Cice G, Tiagliamonte E, Ferrara L, et al. Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controled study. Eur Heart J 2000;21:1259–64.
  30. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol OR Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7–13.
  31. Arumanayagam M, Chan S, Tong S, Sanderson JE. Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial. Cardiovasc Pharmacol 2001;37:48–54.
  32. Metra M, Nardi S, Giubbini R, et al. Effects of short – and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678–87.
  33. Packer M, Coats AJC, Flowler M, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651–58.
  34. Ancker SD, Coats AJC, Roecker EB, et al. Does carvedilol prevent and reverse cardiac cachexia in patients with severe heart failure? Results of the COPERNICUS study (abstract no. 2077). Eur Heart J 2002;(suppl. 23):394.
  35. Mochasci P, Fowler MB, Krum H, et al. Should physicians avoid the use of beta-blockers in patients with heart failure who have diabetes? Results of the COPERNICUS study (abstract no. 3551). Circulation 2001;104(suppl. 2):754.
  36. Rouleau JL, Krum H, Katus HA, et al. Efficacy and safety of carvedilol in patients with low systolic blood pressure in the COPERNICUS study (abstract no. 2082). Eur Heart J 2002;(suppl. 23):396.
  37. Katus HA, Tendera M, Mochasci P, et al. Effect of carvedilol on major clinical events in patients with severe heart failure and an extremely depressed ejection fraction (abstract no. 2700). Eur Heart J 2002;(suppl. 23):514.
  38. Tendera M, Coats AJ, Fowler MB, et al. Effect of gender on the outcome of patients with severe heart failure treateed with carvedilol: results of the COPERNICUS study (abstract no. 858–5). J Am Coll Cardiol 2002;39(suppl. 5A):185A.
  39. Krum H, Mochasci P, Katus HA, et al. Is additional neurohumoral antagonism useful in patients with severe chronic heart failure receiving a combination of neurohormonal antagonists? Results of the COPERNICUS study (abstract). J Am Coll Cardiol 2002;39(suppl. A):177–78A.
  40. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499–506.
  41. Pambukian SV, Aminbakhsh A, Thompson SR, et al. Carvedilol improves functional class in patients with severe left ventricular dysfunction referred for heart transplantation. Clin Transplant 1999;13:426–31.
  42. Angermann CE, Costard-Jaeckle A, Deng MC, et al. Is carvedilol safe and efficacious in severe heart failure. Patients accepted for heart transplantation ? (abstract no. 295). J Heart Lung Transplant 2001;20:250–51.
  43. Di Lenarda A, Sabbani G, Salvatore L, et al. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol 1999;33:1926–34.
  44. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385–90.
  45. Sharpe N, Sendon JLL, Colucci WS, et al. Effects of carvedilol on clinical outcome in patients with left ventricular dysfunction after myocardial infarction: the CAPRICORN study (abstract no. 1642). Circulation 2001;104(suppl. 17):343.
  46. Sackner-Bernstein J, Ford J, Robertson M, et al. Effect of carvedilol on major cardiovascular events in post-infarction patients treated with angiotensin converting enzyme inhibitor: further analysis of the CAPRICORN trial (abstract anmd poster). 52nd Annual Scientific Session of the American College of Cardiology. 2003 Mar 30–Apr 2; Chicago (IL).
  47. MCMurray JJ, Dargie HJ, Ford I, et al. Carvedilol reduces supraventricular and ventricular arrhythmias after myocardial infarction: evidence from the CAPRICORN study (abstract no. 3303). Circulation 2001;104(suppl. 17):700.
  48. Doughty RN, Whalley GA, Walsh H, et al. Effects of carvedilol on left ventricular remodeling in patients following acute myocardial infarction: the CAPRICORN echo substudy (abstract no. 2447). Circulation 2001;104(suppl. 17):517.
  49. Lechat P, Packer M, Chalon S, et al. Clinical effects of b-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind placebo-controlled, randomized trials. Circulation 1998;98:1184–91.
  50. Doughty RN, Rodgers A, Sharpe N, et al. Effects of beta-blocker therapy on mortality in patients with heart failure: a systematic overview of randomized controlled trials. Eur Heart J 1997;18:560–65.
  51. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27–34.
  52. Cleophas TJ, Zwinderman AH. Beta-blockers and heart failure: meta-analysis of mortality trials. Int J Clin Pharmacol Ther 2001;39:383–88.
  53. Bouzamondo A, Hulot JS, Sanchez P, Lechat P. Beta-blocker benefit according to severity of heart failure. Eur J Heart Fail 2003;5:281–89.
  54. Lee S, Spencer A. Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis. J Fam Pract 2001;50:499–504.
  55. Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001;3:351–57.
  56. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001;134:550–60.
  57. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003;41:1529–38.
  58. Shmidt BM, Janson CP, Wehling M. Assuming the worst may not be bad at all: carvedilol in heart failure treatment. Eur J Clin Pharmacol 1998;54:281–85.
  59. Hart SM. Influence of beta-blockers on mortality in chronic heart failure. Ann Pharmacother 2000;34:1440–51.
  60. Packer M, Antonopolous GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 2001;141:899–907.
  61. Krum H, Coats AJ, Fowler MB, et al. Safety and tolerability of carvedilol in patients with severe heart failure: results of the COPERNICUS study (abstract no. 3383). Circulation 2001;104 9(suppl. 17):717.
  62. Krum H, Roecker EB, Mochasci P, et al. Effects of initiating carvedilol in patients with severe heart failure: results from the COPERNICUS study. JAMA 2003;289:712–18.
  63. Krum H, Ninio D, MacDonald P. Baseline predictors of tolerability to carvedilol in patients with chronic heart failure. Heart 2000;84:615–19.
  64. Matsuda N, Endo Y, Uchida Y, et al. Plasma brain natriuretic peptide levels predict tolerance to carvedilol in patients with severe heart failure (abstract no. 3043). Circulation 2000;102(suppl. 2):627–28.
  65. Metra M, Giubbini R Nodari S, et al. Differential effects of b-blockers in patients with heart failure: a prospective, randomized double-blind comparison of the metoprolol versus carvedilol. Circulation 2000;102:546–51.
  66. Hunt SA, Backer DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001;104:2996–3007.
  67. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure: Task Force for the Diagnosis and Treatment of Chronic Heart Failure. European Society of Cardiology. Eur Heart J 2001;22:1527–60.




Бионика Медиа